|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Thyroid Neoplasm
|
0.680 |
Biomarker
|
disease |
BEFREE |
Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer.
|
26259532 |
2016 |
|
Thyroid Neoplasm
|
0.680 |
Biomarker
|
disease |
BEFREE |
Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples.
|
24834793 |
2015 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
KRAS(S65N) was identified for the first time in thyroid cancer and could activate mitogen-associated protein kinase (MAPK).
|
24798740 |
2014 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
The results indicate KRAS mutant subpopulations are present in a large number of thyroid tumors, a fact previously unrecognized.
|
22930660 |
2014 |
|
Thyroid Neoplasm
|
0.680 |
CausalMutation
|
disease |
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
Fourteen FNMTCs in patients from seven families were analyzed in terms of involvement of the four susceptibility loci, and 63 thyroid cancer tumors [FNMTC (29) and NMTC (34)] were evaluated for the occurrence of mutations in BRAF, and H-, N-, and K-RAS, using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing.
|
21826673 |
2012 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunitinib was evaluated in a panel of thyroid cancer cell lines harboring wild-type KRAS and BRAF genes, the RET/PTC1 rearrangement, the G12R KRAS, or the V600E BRAF mutation.
|
22442268 |
2012 |
|
Thyroid Neoplasm
|
0.680 |
CausalMutation
|
disease |
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Thyroid Neoplasm
|
0.680 |
CausalMutation
|
disease |
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
LHGDN |
Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
|
17943694 |
2007 |
|
Thyroid Neoplasm
|
0.680 |
CausalMutation
|
disease |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Thyroid Neoplasm
|
0.680 |
GeneticVariation
|
disease |
LHGDN |
Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
|
16756473 |
2006 |
|
Thyroid Neoplasm
|
0.680 |
Biomarker
|
disease |
CTD_human |
Agent-specific ras oncogene activation in rat thyroid tumours.
|
3078959 |
1988 |
|
Thyroid Neoplasm
|
0.680 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thyroid Neoplasm
|
0.680 |
CausalMutation
|
disease |
CGI |
|
|
|